Abstract
It is well-known fact that oral antidiabetics lose the inefficacy in monotherapy, so it is necessary to combine different types of antidiabetic drugs, sometime seven in smaller doses. Other comorbidities of ten present in type 2 diabetes, arterial hypertension, dyslipidaemia, coagulation disorders and others require complex pharmacological treatment.
It is certainly good to treat everything, but it is also necessary to ensured hat the patient is taking the medication. If the patient does not want to take all the recommended medication, it is appropriate to set priorities to use at least the most important.
For the initial phase of treatment of type 2 diabetes, a combination of antidiabetic agents from different groups is currently recommended in a number of situations. Therefore, it is possible to use combined oral antidiabetic drugs that can combine effects of metformin and one of the 2nd line drugs, in particular dipeptidyl peptidase (DPP-4) inhibitors, sodium-glucose cotransporter (SGLT-2) inhibitors or pioglitazone.
It is a well-known fact that a fixed combination of drugs increases the adherence of the patient and hence the success of the treatment.